The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial
The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial
复制标题
DOI：
10.1161/01.atv.17.4.715
复制
发表时间：
1997-04-01
影响因子：
8.7
通讯作者：
Hodis, HN
中科院分区：
文献类型：
--
作者：
Alaupovic, P;Mack, WJ;Hodis, HN
我们之前已经在一个高胆固醇血症（190 - 295 mg/dL）和有记录的冠状动脉疾病的动脉粥样硬化消退研究（MARS）受试者亚组中证明，洛伐他汀可显著降低富含胆固醇的脂蛋白B（Lp B），但对复杂的、富含胆固醇的载脂蛋白（ape）B（含Lp B（c））（Lp B：C、Lp B：C：E和LpA-II：B：C：D：E的总和）颗粒（由其载脂蛋白组成定义）几乎没有影响。洛伐他汀对含载脂蛋白B的脂蛋白家族的这种不同作用提供了在相同的MARS受试者亚组中确定LpB和LpB（c）与冠状动脉疾病进展的独立关系的机会。在随机化前和治疗2年后，通过冠状动脉造影评估随机接受洛伐他汀（40 mg，每日2次）或匹配安慰剂的受试者，并通过冠状动脉总体变化评分判断总体冠状动脉状态。在洛伐他汀治疗组中，有22例（69%）无进展者和10例（31%）进展者，而在安慰剂组中，有13例（42%）无进展者和18例（58%）进展者（P
We have demonstrated previously in a subset of Monitored Atherosclerosis Regression Study (MARS) subjects with hypercholesterolemia (190 to 295 mg/dL) and documented coronary artery disease that lovastatin significantly reduces cholesterol-rich lipoprotein B (LpB) but has little effect on complex, triglyceride-rich apolipoprotein (ape) B-containing LpB(c) (the sum of LpB:C, LpB:C:E and LpA-II:B:C:D:E) particles defined by their apolipoprotein composition. This differential effect of lovastatin on apoB-containing lipoprotein families offered the opportunity to determine in the same subset of MARS subjects the independent relationship of LpB and LpB(c) with the progression of coronary artery disease. Subjects randomized to either lovastatin (40 mg twice daily) or matching placebo were evaluated by coronary angiography before randomization and after 2 years of treatment, and the overall coronary status was judged by a coronary global change score. In the lovastatin-treated group, there were 22 nonprogressors (69%) and 10 progressors (31%), while in the placebo group 13 subjects (42%) were nonprogressors and 18 (58%) were progressors (P